Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-09-17FDA Approved: OXCARBAZEPINE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's Original Application for generic oxcarbazepine (ANDA 202961).
-
CLINICAL_TRIALS trial_result · 2012-06-20Clinical Trial Update: A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of RWJ-333369 as add-on therapy for partial-onset seizures; the study has complete…
-
CLINICAL_TRIALS trial_result · 2012-06-18Clinical Trial Update: A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. [Phase 3]
Phase 3 study evaluating RWJ-333369 as add-on therapy for partial onset seizures in epilepsy, assessing efficacy and safety. The trial statu…
-
FDA approval · 2012-05-30FDA Approved: ZONISAMIDE — Supplemental Application (Viona Pharmaceuticals Inc)
The FDA approved a supplemental application for zonisamide submitted by Viona Pharmaceuticals Inc under an ANDA. The action updates the labe…
-
CLINICAL_TRIALS withdrawal · 2012-05-28Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating the efficacy and safety of seletracetam in adults with refractory partial-onset seizures has bee…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2012-05-01Clinical Trial Update: Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures [Phase 2]
A Phase 2 trial evaluating BGG492 as adjunctive therapy in patients with refractory partial-onset seizures has been withdrawn.
-
FDA approval · 2012-04-26FDA Approved: LEVETIRACETAM — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for levetiracetam by Aurobindo Pharma Limited, approving this generic product under the ANDA.
-
FDA approval · 2012-04-19FDA Approved: GABAPENTIN — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for gabapentin from Amneal Pharmaceuticals LLC, authorizing changes to the product under an exis…
-
FDA approval · 2012-04-11FDA Approved: LEVETIRACETAM — Original Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved the original application for levetiracetam by Quagen Pharmaceuticals LLC, making a generic version of the antiepileptic availab…
-
FDA approval · 2011-12-28FDA Approved: OXCARBAZEPINE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's supplemental application for oxcarbazepine, allowing the marketing of a generic version of the antiepileptic drug.
-
FDA approval · 2011-12-16FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc., resulting in updated labeling for the drug. K…
-
FDA approval · 2011-11-09FDA Approved: LEVETIRACETAM — Original Application (WG Critical Care, LLC)
The FDA approved an original application for levetiracetam from WG Critical Care, LLC.
-
CLINICAL_TRIALS trial_result · 2011-11-07Clinical Trial Update: Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy [Phase 3]
A Phase 3 trial evaluating retigabine for partial-onset refractory seizures in epilepsy has completed, with efficacy and safety results post…
-
CLINICAL_TRIALS trial_result · 2011-10-25Clinical Trial Update: Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy [Phase 3]
A Phase 3 trial evaluating retigabine as adjunctive therapy for partial-onset seizures in epilepsy has completed, with results posted in 201…
-
FDA approval · 2011-10-13FDA Approved: LEVETIRACETAM — Original Application (Civica, Inc.)
The FDA approved Civica, Inc.'s original application for a generic levetiracetam product. This approval provides a generic version of leveti…
-
FDA approval · 2011-09-27FDA Approved: ZONISAMIDE — Supplemental Application (Viona Pharmaceuticals Inc)
FDA approved a supplemental application for zonisamide submitted by Viona Pharmaceuticals, indicating approval of changes to the product.
-
FDA approval · 2011-09-12FDA Approved: LEVETIRACETAM — Original Application (Apotex Corp.)
FDA approves the original application for a generic levetiracetam (Apotex Corp.), enabling a generic version of the anticonvulsant for seizu…
-
FDA approval · 2011-08-10FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc.
-
FDA approval · 2011-08-10FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., updating the labeling and/or indications for this antiep…
-
CLINICAL_TRIALS trial_result · 2011-07-15Clinical Trial Update: Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures [Phase 3]
Results from a Phase 3 long-term safety study of lacosamide in adults with partial-onset seizures.
-
FDA approval · 2011-06-20FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for LYRICA (pregabalin) submitted by Parke-Davis Div of Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of the Effectiveness and Safety of Topiramate in the Treatment of Children With Epilepsy [Phase 3]
This Phase 3 study assessed the effectiveness and safety of topiramate in children with epilepsy and has completed.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures [Phase 2]
A Phase 2 study evaluating the efficacy and safety of adding topiramate to existing therapy in patients with difficult-to-treat partial-onse…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures. [Phase 2]
This clinical trial update reports the completion of a Phase 2 study evaluating topiramate as add-on therapy for difficult-to-treat partial-…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures. [Phase 2]
Phase 2 trial evaluating the efficacy and safety of add-on topiramate in patients with difficult-to-treat epilepsy and partial-onset seizure…